Terbutaline: level the playing field for inhaled β2-agonists by introducing a dosing and urine threshold
Research output: Contribution to journal › Letter › Research › peer-review
Standard
Terbutaline: level the playing field for inhaled β2-agonists by introducing a dosing and urine threshold. / Jacobson, Glenn A; Hostrup, Morten.
In: British Journal of Sports Medicine, Vol. 51, No. 18, 2017, p. 1323-1324.Research output: Contribution to journal › Letter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Terbutaline: level the playing field for inhaled β2-agonists by introducing a dosing and urine threshold
AU - Jacobson, Glenn A
AU - Hostrup, Morten
N1 - CURIS 2017 NEXS 230
PY - 2017
Y1 - 2017
N2 - Terbutaline, a short-acting β2-agonist similar to salbutamol, is widely used in Europe in the treatment of asthma and exercise-induced bronchoconstriction. Unlike salbutamol, terbutaline requires therapeutic use exemption (TUE) for therapeutic inhaled use in competitive sport. There is now compelling evidence that supratherapeutic use of terbutaline is performance enhancing, via oral dosing and inhalation. It is likely that the ergogenic effects of terbutaline are class specific for all β2-agonists. The World Anti-Doping Agency (WADA) has introduced dosing and urine threshold and decision limits for other common β2-agonists. This allows athletes to use these drugs for therapeutic purposes while minimising the potential for doping and administrative burden of TUEs. However, no such threshold limits currently exist for terbutaline. For terbutaline, athletes can be granted a TUE, then administer the drug via inhalation at supratherapeutic doses with impunity. The introduction of threshold dosing and urine limits for terbutaline should be a high priority, given the drug's demonstrated ergogenic effects.
AB - Terbutaline, a short-acting β2-agonist similar to salbutamol, is widely used in Europe in the treatment of asthma and exercise-induced bronchoconstriction. Unlike salbutamol, terbutaline requires therapeutic use exemption (TUE) for therapeutic inhaled use in competitive sport. There is now compelling evidence that supratherapeutic use of terbutaline is performance enhancing, via oral dosing and inhalation. It is likely that the ergogenic effects of terbutaline are class specific for all β2-agonists. The World Anti-Doping Agency (WADA) has introduced dosing and urine threshold and decision limits for other common β2-agonists. This allows athletes to use these drugs for therapeutic purposes while minimising the potential for doping and administrative burden of TUEs. However, no such threshold limits currently exist for terbutaline. For terbutaline, athletes can be granted a TUE, then administer the drug via inhalation at supratherapeutic doses with impunity. The introduction of threshold dosing and urine limits for terbutaline should be a high priority, given the drug's demonstrated ergogenic effects.
U2 - 10.1136/bjsports-2016-096453
DO - 10.1136/bjsports-2016-096453
M3 - Letter
C2 - 27461883
VL - 51
SP - 1323
EP - 1324
JO - British Journal of Sports Medicine
JF - British Journal of Sports Medicine
SN - 0306-3674
IS - 18
ER -
ID: 164453731